

*Gellan gum and its methacrylated derivatives as *in situ* gelling mucoadhesive formulations of pilocarpine: *In vitro* and *in vivo* studies*

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Agibayeva, L. E., Kaldybekov, D. B., Porfiryeva, N. N., Garipova, V. R., Mangazbayeva, R. A., Moustafine, R. I., Semina, I. I., Mun, G. A., Kudaibergenov, S. E. and Khutoryanskiy, V. V. ORCID: <https://orcid.org/0000-0002-7221-2630> (2020) Gellan gum and its methacrylated derivatives as *in situ* gelling mucoadhesive formulations of pilocarpine: *In vitro* and *in vivo* studies. International Journal of Pharmaceutics, 577. 119093. ISSN 0378-5173 doi: 10.1016/j.ijpharm.2020.119093 Available at <https://centaur.reading.ac.uk/89013/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

Published version at: <https://www.sciencedirect.com/science/article/pii/S0378517320300776>

To link to this article DOI: <http://dx.doi.org/10.1016/j.ijpharm.2020.119093>

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading
Reading's research outputs online

1 **Gellan gum and its methacrylated derivatives as *in situ* gelling mucoadhesive**
2 **formulations of pilocarpine: *in vitro* and *in vivo* studies**

3 Laura E. Agibayeva^{a,b,1}, Daulet B. Kaldybekov^{a,b,1}, Natalia N. Porfiryeva^c, Venera R. Garipova^c,
4 Rauash A. Mangazbayeva^b, Rouslan I. Moustafine^{c,d}, Irina I. Semina^d, Grigoriy A. Mun^b, Sarkyt E.
5 Kudaibergenov^e, Vitaliy V. Khutoryanskiy^{a,c,*}

6 ^a *Reading School of Pharmacy, University of Reading, Whiteknights, RG6 6AD Reading, United*
7 *Kingdom*

8 ^b *Department of Chemistry and Chemical Technology, Al-Farabi Kazakh National University,*
9 *050040 Almaty, Kazakhstan*

10 ^c *Institute of Pharmacy, Kazan State Medical University, 16 Fatykh Amirkhan Street, 420126*
11 *Kazan, Russian Federation*

12 ^d *Central Research Laboratory, Kazan State Medical University, 6/30 Tolstogo Street, 420012*
13 *Kazan, Russian Federation*

14 ^e *Institute of Polymer Materials and Technology, 050013 Almaty, Kazakhstan*

15 ¹These authors contributed equally.

16

17 ***Corresponding author**

18 Postal address: Reading School of Pharmacy, University of Reading, Whiteknights, PO Box 224,
19 RG6 6AD Reading, United Kingdom
20 E-mail address: v.khutoryanskiy@reading.ac.uk (V.V. Khutoryanskiy)
21 Phone: +44(0) 118 378 6119
22 Fax: +44(0) 118 378 4703
23

24 **Abstract**

25 Gellan gum was chemically modified by the reaction with methacrylic anhydride to produce
26 derivatives with 6, 14 and 49 % methacrylation. The structure and substitutions degrees of these
27 derivatives were confirmed by ^1H NMR- and FTIR-spectroscopy. These derivatives are more
28 hydrophobic compared to pristine gellan and form turbid solutions in water. *In vitro* study performed
29 with formulations of sodium fluorescein containing gellan gum and its methacrylated derivatives
30 indicated that methacrylation enhances their retention on bovine conjunctival mucosa. *In vivo*
31 experiments with the formulations of pilocarpine hydrochloride containing gellan gum and
32 methacrylated derivatives have demonstrated that all polymers enhance the drug effect significantly,
33 but best performance is observed for the polysaccharide with 6% methacrylation.

34 **Keywords:** gellan gum, methacrylation, *in situ* gelling, mucoadhesion, ocular drug delivery,
35 pilocarpine, glaucoma, wash out₅₀.

36

37 **1. Introduction**

38 Glaucoma is a group of ophthalmic conditions accompanied with an increased intraocular
39 pressure, which may eventually result in a damage of an optic nerve and potentially leads to blindness.
40 There are two types of this ocular condition called open-angle glaucoma and angle-closure glaucoma.
41 Unfortunately, glaucoma cannot be fully cured but if medication is administered regularly, it can
42 control the intraocular pressure and prevent the damage of the optic nerve. There are several types of
43 therapeutic agents that are used to treat glaucoma, which include prostaglandin analogues, beta-
44 blockers, carbonic anhydrase inhibitors, sympathomimetics and miotics. All these medications are
45 administered as eye drops (Moiseev et al., 2019).

46 Pilocarpine is a miotic that opens up an inefficient channel in the trabecular meshwork.
47 Typically, pilocarpine is used for treatment of angle-closure glaucoma and adult patients with this
48 condition are recommended to apply pilocarpine eye drops up to 4 times a day to control the
49 intraocular pressure (British National Formulary, 2018). This requirement for frequent application of
50 eye drops makes the therapy very inconvenient and less patient compliant. Advanced drug delivery
51 strategies are needed to reduce the need for such a frequency for ocular administration of pilocarpine.

52 When conventional eye drops are used, drug retention in the ocular environment is generally
53 very poor (Wilson, 2004). This is related to continuous production of tear fluid, blinking reflex,
54 nasolacrimal drainage and poor permeability of ocular membranes. Therefore, the bioavailability of
55 drugs administered via conventional eye drops is less than 5% (Hillery et al., 2001). Ocular
56 bioavailability of eye drops could be substantially improved when mucoadhesive polymers are used
57 as a part of the formulation. These materials have the ability to adhere to mucosal tissues on the eye
58 and ensure better retention of the formulation on ocular surfaces leading to more efficient drug
59 absorption (Hornof et al, 2003; Ludwig, 2005; Laffleur et al, 2015; Tighsazzadeh et al, 2019).

60 All water-soluble polymers exhibit some mucoadhesive properties (Khutoryanskiy, 2011,
61 2014). Polyelectrolytes (cationic and anionic) usually are more adhesive than non-ionic polymers.
62 Adhesiveness of formulations and their retention on ocular tissues also depends on other factors such

63 as polymer molecular weight, chain flexibility, presence of cross-links, rheological properties of eye
64 drops, etc. (Ludwig, 2005). Some polymers could also be used to formulate *in situ* gelling systems
65 that are liquids during storage but form viscous gels upon administration on the eye, which leads to
66 substantial improvements in their retention on ocular surfaces (Thrimawithana et al., 2012; Kirchhof
67 et al., 2015; Al Khateb et al., 2016; Wu et al., 2019).

68 Gellan is a linear anionic hetero-polysaccharide that consists of tetra-saccharide repeating units
69 including 1,3- β -D-glucose, 1,4- β -D-glucuronic acid, 1,4- β -D-glucose and 1,4- α -L-rhamnose (Bajaj
70 et al., 2007; Morris et al., 2012). Gel-forming properties of gellan, as well as its biocompatibility,
71 allow using this polysaccharide not only in the food and cosmetic industry, but also for biomedical
72 purposes, including drug delivery (Omoto et al., 1999; Rupenthal et al., 2011a; Ferris et al., 2013;
73 Osmałek et al., 2014; Kudaibergenov et al, 2019). *In situ* gelling properties of gellan based
74 formulations have been considered for application in ocular drug delivery in several publications
75 (Rozier et al., 1997; Carlfors et al., 1998; Paulsson et al., 1999; Balasubramaniam et al., 2003;
76 Rupenthal et al., 2011a, 2011b; Fernández-Ferreiro et al., 2015). Some attempts were also reported
77 on chemical modification of gellan aiming to enhance its mucoadhesive properties. Yadav et al.
78 (2014) synthesised gellan-thioglycolic acid conjugate and established that thiolation of gellan gum
79 decreased its sensitivity to Ca^{2+} -induced gelation. However, formulations based on gellan thioglycolic
80 acid conjugate containing metronidazole showed 1.82-fold greater mucoadhesive strength compared
81 to parent polymer. Jalil et al (2019) conjugated gellan gum with 2-(2-amino ethyldisulfanyl) nicotinic
82 acid and used it for formulating mucoadhesive films for vaginal administration.

83 Recently, Kolawole et al. (2018) reported the possibility of enhancing mucoadhesive properties
84 of chitosan by its methacrylation. Methacrylated chitosan exhibited greater adhesion to and retention
85 on porcine bladder mucosa. Methacrylated gellan has previously been used for preparation of
86 chemically cross-linked hydrogels (Coutinho et al., 2010); however, it has not been explored with
87 regards to the effect of methacrylation on mucoadhesive properties.

88 This paper reports the synthesis of methacrylated gellan and evaluates the possibility of its
89 retention on freshly excised bovine conjunctival tissue using fluorescent microscopy *in vitro*. It also
90 evaluates pilocarpine hydrochloride containing *in situ* gelling formulations with gellan and
91 methacrylated gellan *in vivo* in rabbits.

92 **2. Materials and methods**

93 **2.1. Materials**

94 Gellan gum PhytagelTM (GG, MW~1000 kDa), methacrylic anhydride (MA), fluorescein sodium
95 salt (NaFl) and pilocarpine hydrochloride were purchased from Sigma-Aldrich (Gillingham, UK). All
96 other chemicals were of analytical grade and used without further purification.

97 **2.2. Synthesis of methacrylated gellan gum**

98 Methacrylated gellan gum (MeGG) was synthesised by reacting gellan gum (GG) with
99 methacrylic anhydride (MA) at various molar ratios to produce derivatives with low (LMeGG),
100 medium (MMeGG) and high (HMeGG) degrees of substitution using a protocol reported by Coutinho
101 et al. (2010) with slight modifications. Briefly, 0.5 g (0.672 mmol) GG was dissolved in 100 mL of
102 deionised water in a round-bottom flask at 90 °C for 30 min under constant stirring until a transparent
103 homogeneous solution formed. Then, the temperature of the mixture was decreased to 50 °C and the
104 desired amounts of MA were added dropwise. **Table 1** presents the data on the feed ratios used in
105 this synthesis. The reaction proceeded at 50 °C and shaken at 100 rpm for 6 h. pH was maintained at
106 8.0 throughout the reaction by adding 5.0 M sodium hydroxide. The final product was re-dispersed
107 in distilled water, purified by dialysis against distilled water (5 L; 8 changes) during 48 h using a
108 dialysis membrane tube (12–14 kDa molecular weight cut-off; Medicell Membranes Ltd, UK),
109 lyophilised and stored in a fridge for further use.

110

111

112

113

114 **Table 1**

115 Feed ratios for the synthesis of methacrylated gellan gum (MeGG).

Parameters	LMeGG	MMeGG	HMeGG
Concentration of gellan gum (GG)	0.5 g	0.5 g	0.5 g
Amount of methacrylic anhydride	1.035 g (1 mL)	2.59 g (2.5 mL)	4.14 g (4 mL)
Moles of MA per unit mole GG	5.0	12.5	20.0

116

117 **2.3. Nuclear magnetic resonance spectroscopy (^1H NMR)**118 Solutions of gellan gum and its methacrylated derivatives (0.25% w/v) were prepared in D_2O .119 Solution of methacrylic anhydride (1% v/v) was prepared in CD_3Cl . ^1H NMR spectra of samples were
120 recorded using a Bruker DPX 400 MHz NMR-spectrometer (Bruker, UK) at 50 °C.121 The methyl group ($-\text{CH}_3$) on the rhamnose ring from GG repeating unit was used as a reference
122 (δ 1.27 ppm) and the degree of substitution (DS%) was quantified using the following equation:

$$123 \quad DS\% = \frac{\frac{1}{2}I_{\text{double bond(methacrylate)}}}{n_{\text{OH repeating unit}}} \times 100\% \quad (1)$$

124 where $I_{\text{double bond(methacrylate)}}$ is the integration of the double bond proton peak of the methacrylate
125 groups and $I_{\text{CH}_3(\text{rhamnose})}$ is the integration of the reference peak with the number of protons in each
126 peak, respectively; $n_{\text{OH repeating unit}}$ is the number of reactive $-\text{OH}$ sites in GG structure.127 **2.4. Fourier transform infra-red (FTIR) spectroscopy**128 FTIR spectra of unmodified and modified gellan gums were recorded on Nicolet iS5 FTIR
129 spectrometer (Thermo Scientific, UK) using an iD5 attenuated total reflectance (ATR) accessory

130 equipped with a diamond crystal. Samples were scanned from 4000 to 500 cm⁻¹; the absorbance mode
131 was used and the spectral resolution was 4 cm⁻¹.

132 **2.5. Dynamic light scattering (DLS)**

133 Aggregation of unmodified and modified gellan gum was examined using dynamic light
134 scattering (DLS) with a Zetasizer Nano-NS (Malvern Instruments, UK) at 25 °C. Samples were
135 prepared by dispersing lyophilised polymers in deionised water to form 0.1; 0.5 and 1 mg/mL
136 solutions and left stirring overnight. The pH of formed dispersions was adjusted to 2; 4; 6 and 8 by
137 addition of HCl and NaOH solutions.

138 **2.6. *Ex vivo* bovine mucoadhesion studies**

139 **2.6.1. Preparation of eye drop solutions**

140 In order to demonstrate the applicability of modified and unmodified *in situ* gelling gellan gum
141 (GG) formulations for ocular drug delivery, fluorescein sodium salt (NaFl) was employed as a model
142 compound to load into GG and MeGG solutions. Briefly, 30 mg (0.6% w/v) of GG and its
143 methacrylated derivatives were dissolved in 5 mL aqueous solutions of NaFl (1 mg/mL in deionised
144 water) at a constant stirring and room temperature until homogenous solutions formed.

145 Simulated tear fluid (STF) used to wash a mucosal surface was prepared as reported previously
146 (Lin and Sung, 2000). STF was composed of NaCl (6.7 g), NaHCO₃ (2.0 g), and CaCl₂ · 2H₂O (0.08
147 g) dissolved in 1000 mL of deionised water (pH 7.4) and the solution was kept at 37 °C throughout
148 the experiments.

149 **2.6.2. Retention on bovine conjunctival mucosa**

150 The mucosal retention of modified and unmodified gellan gum (GG) on *ex vivo* bovine
151 conjunctival tissues was evaluated using the methodology developed in-house with minor
152 modifications (Tonglairoum et al., 2016). Whole bovine eyeballs with conjunctivae were acquired
153 from P.C. Turner Abattoirs (Farnborough, UK) immediately after animal slaughter, packed and
154 transported to the laboratory in a cold polystyrene container. The tissues were subsequently defrosted

155 upon delivery and bovine eyelids were carefully dissected within 2 h using a sharp blade, avoiding
156 contact with the mucosal surface. Each eyelid mucosa (palpebral conjunctiva) was rinsed with 1 mL
157 STF solution, mounted on a glass slide with mucosal side facing upward, placed in Petri dishes,
158 wrapped with cling film to prevent dehydration and stored in a fridge. All tissues were used within
159 24 h of retrieval.

160 Experiments were conducted with a conjunctival tissue already mounted on a glass slide placed
161 on a substrate at an angle of 45° and maintained at 37 °C in an incubator. Aliquots (200 µL) from
162 NaFl-loaded modified and unmodified gellan gum formulations and free NaFl stock solutions were
163 aspirated and pipetted onto a 2 × 2 cm² piece of conjunctival mucosa and irrigated with STF solution
164 at a flow rate of 200 µL/min using a syringe pump over 60 min of total washing time. Fluorescence
165 microscopy images of whole tissue were taken at predetermined time points after each wash using a
166 Leica MZ10F stereo-microscope (Leica Microsystems, UK) with Leica DFC3000G digital camera at
167 1.6× magnification and 12 ms exposure time, fitted with a GFP filter (blue, $\lambda_{\text{emission}} = 520$ nm). The
168 microscopy images were then analysed with ImageJ software by measuring the fluorescence pixel
169 intensity after each wash with STF. The pixel intensity of the blank samples (i.e. the background
170 microscopy images recorded for each conjunctival mucosa without a fluorescent test material) was
171 deducted from each measurement and data were normalised and converted into fluorescent intensity
172 values using the following equation:

$$173 \quad \text{Fluorescence intensity} = \frac{I - I_b}{I_0 - I_b} \times 100\% \quad (2)$$

174 where I_b is the background fluorescence intensity of a given tissue sample (a blank sample); I_0 is the
175 initial fluorescence intensity of that sample (a tissue sample with mucoadhesive test material on it
176 prior to the start of first wash out); and I is the fluorescence intensity of that tissue sample with a
177 mucoadhesive fluorescent material after each wash out cycle.

178 In addition, wash out₅₀ (WO₅₀) values of fluorescent mucoadhesives were quantified *via*
179 extrapolation of the average wash-off profiles to 50 % using polynomial fitting (5th order) and
180 Wolfram Alpha (a computational knowledge engine). These WO₅₀ values are used to evaluate and
181 compare formulations retention efficacy on mucosal surfaces, which depict the volume of simulated
182 tear fluid necessary to wash out 50 % of a mucoadhesive formulation from a substrate (Mun et al.,
183 2016).

184 All measurements were carried out in triplicate and the mean values \pm standard deviations were
185 quantified and evaluated statistically.

186 **2.7. *In vivo* experiments**

187 Solutions of polymers were prepared by dissolving 0.03 g of each polymer in 5 mL deionised
188 water. Then 0.05 g of pilocarpine hydrochloride was added to each sample to make 1 % solutions and
189 these were left stirring overnight before use. *In vivo* experiments with these solutions were conducted
190 in chinchilla rabbits of either sex (3700–3800 g, n = 4) according to the methodology adapted from
191 (Lin et al., 2004). These experiments were approved by Kazan State Medical University ethics
192 committee (approval No.5 from 28th May 2012) and were conducted following the ARVO Statement
193 for the Use of Animals in Ophthalmic and Visual Research. Prior to experiments, rabbits were housed
194 in standard cages and allowed free access to food and water. During the experiments, rabbits were
195 restrained by gently wrapping them in a cotton tissue, where their eyes and eye-lid movements were
196 not restricted. Eye drops (150 μ L) were instilled into rabbit's left eye and their right one served as a
197 control (150 μ L of water were instilled). Digital images were taken at different time points with a
198 web-camera and these were processed with ImageJ software to calculate the difference between the
199 right (D_{right} , mm) and left (D_{left} , mm) pupil diameters:

200
$$\Delta = D_{right} - D_{left} \quad (3)$$

201 Each experiment was conducted for 210 min; then areas under the decrease in pupil diameter
202 versus time profile in 210 mins (AUC₁₅₋₂₁₀) were calculated using the trapezoidal rule.

203


204 **2.8. Statistical analysis**

205 All measurements were performed in triplicates and data expressed as mean \pm standard
206 deviation (unless specified otherwise). Data were compared for significance using two-tailed
207 Student's *t*-test and a one-way analysis of variance (ANOVA) with GraphPad Prism statistical
208 analysis software (version 7.0; GraphPad Software Inc.), where *p* < 0.05 was set as the statistical
209 significance criterion.

210 **3. Results and discussion**

211 **3.1. Synthesis of methacrylated gellan gum (MeGG) derivatives**


212 Methacrylated gellan was synthesised by reaction with methacrylic anhydride (**Fig. 1A**).
213 Following purification by dialysis, methacrylated derivatives were studied using ¹H NMR
214 spectroscopy (**Fig. 1B**). All four spectra displayed the characteristic peak that corresponds to the
215 methyl (–CH₃) group from rhamnose ring (δ 1.27 ppm), which was used as a reference (Lu et al,
216 2019).



218 **Figure 1.** Synthesis and characterisation of methacrylated gellan gum (MeGG). (A) Schematic
 219 illustration of the methacrylation reaction. Please note that schematic structure show only one
 220 possibility of methacrylic reaction anhydride with $-\text{CH}_2\text{-OH}$ groups of gellan gum. In reality it could
 221 react with any OH-group present in gellan gum; (B) ^1H NMR spectra of gellan gum (GG) with low
 222 (LMeGG), medium (MMeGG) and high (HMeGG) degrees of methacryylation recorded in D_2O at 50
 223 °C. The characteristic methyl peak (a) from rhamnose structural unit and methyl group (b) of the
 224 methacrylic anhydride (MA) were detected at 1.27 and 1.91 ppm, respectively, and methylidene
 225 ($\text{CH}_2=$) peaks (c) of MA were identified at 5.72 and 6.13 ppm. Some broadening of methyl peak at
 226 1.27 ppm could be related to partial aggregation of more hydrophobic methacrylated macromolecules.

227 Methacrylation was confirmed by the appearance of distinctive methacryloyl (**CH₂=C(CH₃)**–) 228 group peaks (δ 5.72 and 6.13 ppm) and a peak corresponding to the –CH₃ group of the methacrylate 229 moieties on the modified GG segment (δ 1.91 ppm). This is in good agreement with ¹H NMR data 230 reported in the literature (Coutinho et al., 2010; Kolawole et al., 2018). The degree of substitution 231 was quantified by determining the ratio of integrated methylidene group (CH₂=C) peaks on the 232 methacrylate conjugate over the –CH₃ group on the rhamnose ring. The LMeGG, MMeGG and 233 HMeGG displayed DS at 6, 14 and 49 %, respectively. The yields of methacrylated derivatives were: 234 LMeGG (31 %), MMeGG (22 %) and HMeGG (11 %). This decrease in the yield shows a similar 235 trend to the previously reported methacrylated chitosan (Kolawole et al., 2018).

236 The methacrylation of GG was further confirmed by FTIR spectroscopy (**Fig. 2**). The FTIR 237 spectra of modified and unmodified GG display broad –OH stretching peaks appeared above 3000 238 cm^{–1} and skeletal vibration involving the C–O stretching at 1030 cm^{–1}, which are typical for all 239 polysaccharides. The peaks at 1220, 1300-1470 cm^{–1} are due to C–C stretching and CH bending, 240 respectively. The characteristic double bond peak signal observed in the spectra of methacrylated 241 derivatives at 1630 cm^{–1} represents C=C stretching in methacrylate moiety of GG, while the 242 absorption band at 1715 cm^{–1} attributed to the carbonyl (C=O) stretching confirming the chemical 243 modification of GG and growth of peak intensity with increasing degree of methacrylation. The peaks 244 at around 2300 cm^{–1} present in the spectra of all samples are typical for atmospheric carbon dioxide.



245

246 **Figure 2.** FTIR spectra of gellan gum (GG) and its methacrylated derivatives (LMeGG, MMeGG
247 and HMeGG)


248 **Solubility of methacrylated gellan gum in water**

249 Unlike parent GG, methacrylated gellan gum derivatives were not fully soluble in water and
250 formed slightly turbid solutions. This is likely related to a slightly hydrophobic nature of methacryloyl
251 moieties and is in agreement with the observations reported for methacrylated chitosan (Kolawole et
252 al., 2018). The solutions of parent and modified gellan gum were evaluated using dynamic light
253 scattering (DLS) at three different concentrations (0.1, 0.5 and 1 mg/mL) and different pHs (2, 4, 6,
254 8), which indicated the presence of highly polydisperse aggregates even in solutions of parent gellan
255 gum (Fig. S1 and S2). The highly polydisperse nature of these aggregates and the presence of particles
256 whose sizes are > 1000 nm did limit the applicability of DLS for accurate characterisation of these
257 colloidal dispersions. The presence of large particles in unmodified gellan gum is likely related to the

258 ability of this polysaccharide to form ordered helices of double strands at low temperatures (Yuguchi
259 et al., 1993). The tendency to aggregate is increased with methacrylation due to partially hydrophobic
260 nature of methacryloyl moieties. More substantial aggregation was observed upon increase in
261 polymer concentrations in all cases and also under very acidic pH (pH 2.0). The aggregation in
262 strongly acidic solutions is likely related to suppression of carboxylic groups ionisation.

263 **3.2. Mucoadhesion studies**


264 The mucosal retention of unmodified and methacrylated gellan gum formulations containing
265 fluorescein sodium (NaFl, 1 mg/mL) and free NaFl solution on freshly isolated bovine conjunctival
266 tissue was evaluated using a wash-off *in vitro* technique with fluorescent detection. This method has
267 been extensively used by our group to investigate the mucoadhesive properties of various materials
268 on mucosal surfaces (Irmukhametova et al., 2011; Al Khateb et al., 2016; Tonglairoum et al., 2016;
269 Kolawole et al., 2018; Porfiryeva et al, 2019). **Fig. 3** shows exemplar fluorescence microphotographs
270 of the retention of gellan gum and its methacrylated derivatives (LMeGG, MMeGG, HMeGG) and
271 NaFl (used as a control) on *ex vivo* bovine conjunctival mucosa taken after each washing with STF
272 solutions (pH 7.4; flow rate 200 μ L/min) over 60 min.



273

274 **Figure 3.** Exemplary fluorescent microphotographs showing mucosal retention of unmodified and
 275 methacrylated gellan gum (GG, LMeGG, MMeGG and HMeGG) formulations with fluorescein
 276 sodium (NaFl), and free NaFl (served as a control) on freshly excised bovine conjunctival tissue as
 277 washed with simulated tear fluid (pH 7.4; 200 µL/min) over 60 min. Scale bars are 200 µm.

278 The fluorescent images were then analysed using ImageJ software and fluorescence intensity
 279 values were normalised to 100 % (Fig. 4). During mucoadhesion experiments conducted at 37 °C,
 280 GG and its methacrylated derivatives formed *in situ* gels and the percentage of retention on mucosal
 281 tissues was estimated. It was revealed that methacrylation enhanced the mucoadhesive properties of
 282 GG on freshly excised bovine conjunctiva. HMeGG displayed significantly greater retention
 283 compared to its unmodified GG ($p < 0.001$), LMeGG ($p < 0.05$) and NaFl solution ($p < 0.0001$).



284

285 **Figure 4.** Mucosal retention of fluorescein sodium (NaFl) from GG, HMeGG, MMeGG and LMeGG,
 286 and NaFl (used as a control) on freshly dissected bovine conjunctival tissue as irrigated with simulated
 287 tear fluid (pH 7.4; 200 µL/min) over 60 min. All values are the means \pm standard deviations of
 288 triplicate experiments. “***” depicts statistical significant differences between samples ($p < 0.001$).

289 Moreover, GG and LMeGG formulations exhibited almost the same retention ability ($p > 0.05$).
 290 They were washed out quicker than HMeGG but showed greater retention than NaFl solution. The
 291 retention of HMeGG and MMeGG on conjunctival mucosa was found not to be significantly different
 292 from each other ($p > 0.05$) expressing a similar retention trend and increased fluorescence intensity
 293 until the end of washing cycles. Additionally, NaFl solution showed significantly lower retention
 294 capability, approximately 85 % of it was washed out from the mucosal tissue. The remaining NaFl
 295 could be associated to its ability to stain mucosal surface as it is usually used in clinical practice for
 296 the diagnosis of ocular disorders (Korb et al., 2008).

297 In this study, the retention of GG, LMeGG, MMeGG and HMeGG on *ex vivo* bovine
 298 conjunctivae was also determined using a quantitative WO₅₀ method developed by Mun et al. (2016).

299 WO₅₀ describes the volume of bio-relevant fluid required to wash out 50 % of the formulation from
300 the mucosal surfaces. By analysing individual wash-off profiles for each NaFl-loaded GG, LMeGG,
301 MMeGG and HMeGG excipients as well as free NaFl, the WO₅₀ values were determined: 18 mL (R²
302 = 0.9934), 23 mL (R² = 0.9979), 65 mL (R² = 0.9977), 75 mL (R² = 0.9988) and 3 mL (R² = 0.9958),
303 respectively. According to these data, HMeGG has the highest WO₅₀ value and this demonstrates its
304 superior retention behaviour compared to other samples. This is likely attributed to the fact that
305 methacrylation (similarly to acrylation) enhances the adhesion of GG on conjunctival tissues by
306 forming covalent linkages between C–C double bond of GG methacrylate moieties and thiol groups
307 present in conjunctival mucosa (Davidovich-Pinhas and Bianco-Peled, 2011; Brannigan and
308 Khutoryanskiy, 2017; Kolawole et al., 2018; Porfiryeva et al, 2019). Therefore, these results confirm
309 the retention properties of methacrylated gellan gum, which could also be used as a potential
310 mucoadhesive formulation in the therapy of ocular disorders.


311 **3.3. *In vivo* studies**

312 *In vivo* studies were performed in rabbits using formulations of pilocarpine hydrochloride
313 (pilocarpine · HCl) prepared with unmodified and modified gellan gum. Pilocarpine · HCl eye drops
314 are mainly used in the treatment of glaucoma and this drug causes pupil constriction. This allows a
315 non-invasive *in vivo* study where the efficiency of different pilocarpine formulations could be
316 compared. Previously, Lin et al. (2004) have reported an *in vivo* study of pilocarpine formulated using
317 sodium alginate, Pluronic F127 and their mixtures and established that the mixture of two polymers
318 significantly improves the drug efficiency and bioavailability.

319 An administration of pilocarpine · HCl containing eye drops in rabbits does indeed cause their
320 pupil constriction (**Fig. 5A**), which could be non-invasively measured using image analysis. **Fig. 5B**
321 shows the difference in pupil diameter Δ recorded as a function of time following administration of
322 different pilocarpine hydrochloride formulations. Despite the apparent ease of these measurements,
323 there are some limitations related to the reaction of eye pupils to environmental light. Any changes
324 in lighting of the environment could result in quick pupil reaction, which explains relatively high


325 values of error bars recorded in these measurements. Nevertheless, the analysis of these data indicates
326 that there is a statistically significant difference between pure pilocarpine · HCl drops and the
327 formulation containing MMeGG ($p < 0.05$), with the later exhibiting a more substantial pupil
328 response at 180 min of experiment. The formulation containing MMeGG also showed greater
329 response compared to unmodified gellan gum ($p < 0.01$).

A



330


B



331

332 **Figure 5.** Exemplary images of rabbit eye with (left eye) and without (right eye) administration of
333 pilocarpine · HCl formulations (A); Δ_{pupil} values recorded in rabbits from 15 to 210 min of
334 experiment following administration of different pilocarpine · HCl formulations (B). “*” and “**”
335 depict statistically significant differences between samples ($p < 0.05$) and ($p < 0.01$), respectively.
336 All values are the mean \pm standard error of the mean (n=4).

337 In order to see the overall performance of all five formulations in the time course of experiments
338 the values of area under the Δ_{pupil} versus time profiles in 15–210 min were calculated (**Fig. 6**). These
339 values showed the difference between these formulations clearer. The formulation containing
340 unmodified GG did show significantly greater efficiency compared to pure pilocarpine · HCl ($p <$
341 0.05). The formulations containing LMeGG and MMeGG showed even better performance than GG,
342 which is likely related to their enhanced mucoadhesive properties ($p < 0.0001$ and $p < 0.01$,
343 respectively). However, no significant improvements were found when formulation with HMeGG
344 was used compared to pure pilocarpine · HCl ($p > 0.05$). Also the formulation containing LMeGG
345 did exhibit significantly greater performance compared to HMeGG ($p < 0.05$). The poor performance
346 of HMeGG could be related to its more hydrophobic nature due to the highest levels of methacrylated
347 groups. The difference between *in vitro* retention data and *in vivo* results observed in this work could
348 also be related to the different active ingredients used in these formulations: sodium fluorescein
349 versus pilocarpine · HCl. This could additionally be related to many other factors such some
350 differences in the nature of mucosal surfaces between *ex vivo* bovine tissues and *in vivo* rabbit tissues
351 (e.g. different thiol content), different tear production *in vivo* versus *in vitro* flow rate used, etc. Also
352 *in vivo* the polymer interaction with the mucosa could affect drug absorption due to possible inhibition
353 effects.



354

355 **Figure 6.** Area under the Δ_{pupil} versus time profiles in 210 min (AUC₁₅₋₂₁₀) for various formulations.

356 “*”, “**” and “****” depict $p < 0.05$, $p < 0.01$ and $p < 0.0001$, respectively, ns – no significance.

357 All values are the means \pm standard error of the mean (n = 4).

358 **4. Conclusions**

359 This study reports the synthesis of methacrylated gellan gum derivatives and their evaluation
 360 as potential mucoadhesive excipients for ocular drug delivery. Gellan gum was modified by reaction
 361 with methacrylic anhydride in order to improve its mucoadhesive properties. The methacrylation was
 362 confirmed using ¹H NMR and FTIR spectroscopic techniques and the degree of substitution was
 363 calculated. It was established that methacrylation makes this polysaccharide more hydrophobic. *In*
 364 *vitro* experiments performed using fluorescence technique indicated significant improvement in the
 365 retention of formulations with methacrylation of gellan gum on ocular mucosa. *In vivo* experiments
 366 conducted with pilocarpine hydrochloride formulations containing gellan gum and methacrylated
 367 derivatives indicated greater performance of the polysaccharide with low degree of modification.

368

369 **Acknowledgements**

370 Chemical Analysis Facility (University of Reading) is thanked for providing access to NMR-
371 spectroscopy instrument. L.E.A., R.A.M and G.A.M acknowledge the Ministry of Education and
372 Science of the Republic of Kazakhstan for the research grants (No. BR05234619 and No.
373 BR05236446). D.B.K. acknowledges the Researcher Links Post-Doctoral Mobility Grant (No.
374 216046068, British Council Newton – Al-Farabi Partnership Programme) and Al-Farabi Kazakh
375 National University for financial support of his postdoctoral fellowships. V.V.K and S.E.K.
376 acknowledge the European Union’s Horizon 2020 research and innovation programme under the
377 Marie Skłodowska-Curie grant agreement Nanopol 823883. V.V.K. and R.I.M. acknowledge the
378 Ministry of Education and Science of the Republic of Tatarstan (Russia) for “Algarysh” grant. P.C.

379 **Appendix A. Supplementary material**

380 The Supplementary Information is available free of charge.

381 **Author contributions**

382 The manuscript was written through contributions of all authors. All authors have given
383 approval to the final version of the manuscript.

384 **Notes**

385 The authors declare no conflict of interest.

386 **ORCID ID of authors**

387 Laura E. Agibayeva: <https://orcid.org/0000-0002-5058-5305>

388 Daulet B. Kaldybekov: <https://orcid.org/0000-0002-7191-5465>

389 Natalia N. Porfiryeva <https://orcid.org/0000-0002-7110-2093>

390 Rauash A. Mangazbayeva: <https://orcid.org/0000-0003-1876-591X>

391 Rouslan I. Moustafine, <http://orcid.org/0000-0002-0916-2853>

392 Sarkyt E. Kudaibergenov: <https://orcid.org/0000-0002-1166-7826>

393 Vitaliy V. Khutoryanskiy: <https://orcid.org/0000-0002-7221-2630>

394

395 **REFERENCES**

396 Al Khateb, K., Ozhmukhametova, E.K., Mussin, M.N., Seilkhanov, S.K., Rakhypbekov, T.K., Lau,
397 W.M., Khutoryanskiy, V. V, 2016. In situ gelling systems based on Pluronic F127/Pluronic
398 F68 formulations for ocular drug delivery. *Int. J. Pharm.* 502, 70–79.
399 <https://doi.org/10.1016/j.ijpharm.2016.02.027>

400 Bajaj, I.B., Survase, S.A., Saudagar, P.S., Singhal, R.S., 2007. Gellan gum: Fermentative
401 production, downstream processing and applications. *Food Technol. Biotechnol.* 45, 341–354.

402 Balasubramaniam, J., Kant, S., Pandit, J.K., 2003. In vitro and in vivo evaluation of the Gelrite®
403 gellan gum-based ocular delivery system for indomethacin. *Acta Pharm.* 53, 251–261.

404 Brannigan, R.P., Khutoryanskiy, V. V., 2017. Synthesis and evaluation of mucoadhesive acryloyl-
405 quaternized PDMAEMA nanogels for ocular drug delivery. *Colloids Surfaces B Biointerfaces*
406 155, 538–543. <https://doi.org/10.1016/j.colsurfb.2017.04.050>

407 British National Formulary, 2018. BNF 76, September 2018 – March 2019. BMJ Group, London.

408 Carlfors, J., Edsman, K., Petersson, R., Jörnving, K., 1998. Rheological evaluation of Gelrite® in
409 situ gels for ophthalmic use. *Eur. J. Pharm. Sci.* 6, 113–119. [https://doi.org/10.1016/S0928-0987\(97\)00074-2](https://doi.org/10.1016/S0928-0987(97)00074-2)

411 Coutinho, D.F., Sant, S. V, Shin, H., Oliveira, J.T., Gomes, M.E., Neves, N.M., Khademhosseini,
412 A., Reis, R.L., 2010. Modified gellan gum hydrogels with tunable physical and mechanical
413 properties. *Biomaterials* 31, 7494–7502. <https://doi.org/10.1016/j.biomaterials.2010.06.035>

414 Davidovich-Pinhas, M., Bianco-Peled, H., 2011. Physical and structural characteristics of acrylated
415 poly(ethylene glycol)-alginate conjugates. *Acta Biomater.* 7, 2817–2825.
416 <https://doi.org/10.1016/j.actbio.2011.04.001>

417 Fernández-Ferreiro, A., González Barcia, M., Gil-Martínez, M., Vieites-Prado, A., Lema, I.,
418 Argibay, B., Blanco Méndez, J., Lamas, M.J., Otero-Espinar, F.J., 2015. In vitro and in vivo
419 ocular safety and eye surface permanence determination by direct and Magnetic Resonance
420 Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan. *Eur. J. Pharm.*
421 *Biopharm.* 94, 342–351. <https://doi.org/10.1016/j.ejpb.2015.06.003>

422 Ferris, C.J., Gilmore, K.J., Wallace, G.G., in het Panhuis, M., 2013. Modified gellan gum hydrogels
423 for tissue engineering applications. *Soft Matter* 9, 3705–3711.
424 <https://doi.org/10.1039/C3SM27389J>

425 Hillery, A.M., Lloyd, A.W., Swarbrick, J., 2001. Drug delivery and targeting for pharmacists and
426 pharmaceutical scientists. CRC Press, Taylor & Francis, Boca Raton.

427 Hornof, M., Weyenberg, W., Ludwig, A., Bernkop-Schnürch, A., 2003. Mucoadhesive ocular insert
428 based on thiolated poly(acrylic acid): development and in vivo evaluation in humans. *J.*
429 *Controlled Release* 89, 419-428
430 <https://www.sciencedirect.com/science/article/pii/S0168365903001354?via%3Dihub>

431 Irmukhametova, G.S., Mun, G.A., Khutoryanskiy, V. V, 2011. Thiolated mucoadhesive and
432 PEGylated nonmucoadhesive organosilica nanoparticles from 3-
433 mercaptopropyltrimethoxysilane. *Langmuir* 27, 9551–9556. <https://doi.org/10.1021/la201385h>

434 Jalil, A., Hussain, M., Le N.-M.N., Laffleur, F., Matusczak, B., Tribus, M., Bernkop-Schnürch,
435 A., 2019. S-protected gellan gum: Decisive approach towards mucoadhesive antimicrobial
436 vaginal films. *Int. J. Biol. Macromolecules* 130, 148-157.

437 Khutoryanskiy, V. V., 2014. Mucoadhesive materials and drug delivery systems, *Mucoadhesive*
438 *Materials and Drug Delivery Systems*. John Wiley & Sons, Ltd, Chichester, UK.
439 <https://doi.org/10.1002/9781118794203>

440 Khutoryanskiy, V. V., 2011. Advances in mucoadhesion and mucoadhesive polymers. *Macromol.*
441 *Biosci.* 11, 748–764. <https://doi.org/10.1002/mabi.201000388>

442 Kirchhof, S., Goepferich, A.M., Brandl, F.P., 2015. Hydrogels in ophthalmic applications. *Eur. J.*

443 Pharm. Biopharm. 95, 227–238. <https://doi.org/https://doi.org/10.1016/j.ejpb.2015.05.016>

444 Kolawole, O.M., Lau, W.M., Khutoryanskiy, V. V, 2018. Methacrylated chitosan as a polymer with
445 enhanced mucoadhesive properties for transmucosal drug delivery. Int. J. Pharm. 550, 123–
446 129. <https://doi.org/https://doi.org/10.1016/j.ijpharm.2018.08.034>

447 Kudaibergenov, S.E., Xu, S., Tatykhanova, G.S., Kudaibergenova, G.M., 2019. Gellan gum
448 immobilized anticancer drugs and gold nanoparticles in nanomedicine. Academ. J. Polym. Sci.
449 2(3), 555588. DOI: 10.19080/AJOP.2019.02.555588.

450 Korb, D.R., Herman, J.P., Finnemore, V.M., Exford, J.M., Blackie, C.A., 2008. An evaluation of
451 the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular
452 surface staining. Eye Contact Lens 34, 61–64. <https://doi.org/10.1097/ICL.0b013e31811ead93>

453 Laffleur, F., Dachs, S., 2015. Development of novel mucoadhesive hyaluronic acid derivate as
454 lubricant for the treatment of dry eye syndrome. Ther Deliv. 6(10),1211-1219. doi:
455 10.4155/tde.15.55.

456 Lin, H.-R., Sung, K.C., 2000. Carbopol/pluronic phase change solutions for ophthalmic drug
457 delivery. J. Control. Release 69, 379–388. <https://doi.org/https://doi.org/10.1016/S0168->
458 3659(00)00329-1

459 Lin, H.-R., Sung, K.C., Vong, W.-J., 2004. In situ gelling of alginate/Pluronic solutions for
460 ophthalmic delivery of pilocarpine. Biomacromolecules 5, 2358–2365.
461 <https://doi.org/10.1021/bm0496965>

462 Lu, Y., Zhao, X., Fang, S., 2019. Characterization, antimicrobial properties and coatings application
463 of gellan gum oxidized with hydrogen peroxide. Foods 8, 31. doi:10.3390/foods8010031

464 Ludwig, A., 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv.
465 Rev. 57, 1595–1639. <https://doi.org/10.1016/j.addr.2005.07.005>

466 Moiseev, V.R., Morrison, W.J.P., Steele, F., Khutoryanskiy, V.V., 2019. Penetration enhancers in
467 ocular drug delivery. Pharmaceutics 11, 131. <https://doi.org/10.3390/pharmaceutics11070321>

468 Morris, E.R., Nishinari, K., Rinaudo, M., 2012. Gelation of gellan - A review. Food Hydrocoll. 28,

469 373–411. <https://doi.org/10.1016/j.foodhyd.2012.01.004>

470 Mun, E.A., Williams, A.C., Khutoryanskiy, V. V., 2016. Adhesion of thiolated silica nanoparticles
471 to urinary bladder mucosa: Effects of PEGylation, thiol content and particle size. *Int. J. Pharm.*
472 512, 32–38. <https://doi.org/10.1016/j.ijpharm.2016.08.026>

473 Omoto, T., Uno, Y., Asai, I., 1999. The latest technologies for the application of gellan gum, in:
474 Nishinari, K. (Ed.), *Physical Chemistry and Industrial Application of Gellan Gum*. Springer
475 Berlin Heidelberg, Berlin, Heidelberg, pp. 123–126. https://doi.org/10.1007/3-540-48349-7_18

476 Osmałek, T., Froelich, A., Tasarek, S., 2014. Application of gellan gum in pharmacy and medicine.
477 *Int. J. Pharm.* 466, 328–340. <https://doi.org/10.1016/j.ijpharm.2014.03.038>

478 Paulsson, M., Hägerström, H., Edsman, K., 1999. Rheological studies of the gelation of
479 deacetylated gellan gum (Gelrite®)) in physiological conditions. *Eur. J. Pharm. Sci.* 9, 99–
480 105. [https://doi.org/10.1016/S0928-0987\(99\)00051-2](https://doi.org/10.1016/S0928-0987(99)00051-2)

481 Porfiryeva, N.N., Nasibullin, S.F., Abdullina, S.G., Tukhbatullina, I.K., Moustafine, R.I.,
482 Khutoryanskiy, V.V., 2019. Acrylated Eudragit® EPO as a novel polymeric excipient with
483 enhanced mucoadhesive properties for application in nasal drug delivery, *Int. J. Pharm.* 562,
484 241–248. <https://doi.org/10.1016/j.ijpharm.2019.03.027>

485 Rozier, A., Mazuel, C., Grove, J., Plazonnet, B., 1997. Functionality testing of gellan gum, a
486 polymeric excipient material for ophthalmic dosage forms. *Int. J. Pharm.* 153, 191–198.
487 [https://doi.org/10.1016/S0378-5173\(97\)00109-9](https://doi.org/10.1016/S0378-5173(97)00109-9)

488 Rupenthal, I.D., Green, C.R., Alany, R.G., 2011a. Comparison of ion-activated in situ gelling
489 systems for ocular drug delivery. Part 1: Physicochemical characterisation and in vitro release.
490 *Int. J. Pharm.* 411, 69–77. <https://doi.org/10.1016/j.ijpharm.2011.03.042>

491 Rupenthal, I.D., Green, C.R., Alany, R.G., 2011b. Comparison of ion-activated in situ gelling
492 systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic
493 study. *Int. J. Pharm.* 411, 78–85. <https://doi.org/10.1016/j.ijpharm.2011.03.043>

494 Thrimawithana, T.R., Rupenthal, I.D., Young, S.A., Alany, R.G., 2012. Environment-sensitive

495 polymers for ophthalmic drug delivery. *J. Drug Deliv. Sci. Technol.* 22, 117–124.

496 [https://doi.org/https://doi.org/10.1016/S1773-2247\(12\)50015-8](https://doi.org/https://doi.org/10.1016/S1773-2247(12)50015-8)

497 Tighsazzadeh, M., Mitchell, J.C., Boateng, J.S., 2019. Development and evaluation of performance

498 characteristics of timolol loaded composite ocular films as potential delivery platforms for

499 treatment of glaucoma. *Int. J. Pharm.* 566, 111–125.

500 <https://doi.org/10.1016/j.ijpharm.2019.05.059>

501 Tonglairoum, P., Brannigan, R.P., Opanasopit, P., Khutoryanskiy, V. V., 2016. Maleimide-bearing

502 nanogels as novel mucoadhesive materials for drug delivery. *J. Mater. Chem. B* 4, 6581–6587.

503 <https://doi.org/10.1039/C6TB02124G>

504 Wilson, C.G., 2004. Topical drug delivery in the eye. *Exp. Eye Res.* 78, 737–743.

505 <https://doi.org/10.1016/j.exer.2003.10.004>

506 Yadav, S., Ahuja, M., Kumar, A., Kaur, H., 2014. Gellan-thioglycolic acid conjugate: Synthesis,

507 characterization and evaluation as mucoadhesive polymer. *Carbohydr. Polym.* 99, 601–607.

508 <https://doi.org/10.1016/j.carbpol.2013.08.068>

509 Yuguchi, Y., Mimura, M., Kitamura, S., Urakawa, H., Kajiwara, K., 1993. Structural characteristics

510 of gellan in aqueous solution. *Food Hydrocoll.* 7, 373–385.

511 [https://doi.org/https://doi.org/10.1016/S0268-005X\(09\)80233-6](https://doi.org/https://doi.org/10.1016/S0268-005X(09)80233-6)

512 Wu, Y., Liu Y., Li, X., Kebebe, D., Zhang, B., Ren, J., Lu, J., Li, J., Du, S., Liu, Z., 2019. Research

513 progress of in-situ gelling ophthalmic drug delivery system. *Asian Journal of Pharmaceutical*

514 *Sciences*, 14, 1-15.

515